Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations

被引:15
|
作者
Li, Aibo [1 ]
Sun, Haopeng [2 ]
Du, Lei [1 ]
Wu, Xiaoxin [1 ]
Cao, Jianqin [1 ]
You, Qidong [2 ]
Li, Yuyan [2 ]
机构
[1] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Ubiquitin-proteasome; Covalent inhibitors; Virtual screening; Pharmacophore; Docking; Molecular dynamics; MULTIPLE-MYELOMA; 20S PROTEASOME; BORTEZOMIB; DESIGN; GENERATION; EFFICACY;
D O I
10.1007/s00894-014-2515-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ubiquitin-proteasome pathway plays a pivotal role in the regulation of cellular protein processing and degradation. Proteasome inhibitors (PIs) have enormous potential to treat multiple myeloma, solid tumors, parasites, inflammation, and immune diseases, which is spurring the development of new types of PIs with enhanced efficacy, fewer side effects, and reduced drug resistance. Nevertheless, virtual screening for covalent PIs has rarely been reported because calculating the covalent binding energy is a challenging task. The aim of this study was to discover new covalent inhibitors of the 20S proteasome. The structures of PIs were manually divided into two parts: a noncovalent binding part resulting from virtual screening, and an epoxyketone group that was pre-selected as a covalent binding part. The SPECS database was screened by noncovalent docking and a pharmacophore model built with the 20S proteasome. After validating the covalent conjugation, 88 hits with epoxyketone were covalently docked into the 20S proteasome to analyze the intermolecular interactions. Four compounds were selected after multiple filtration and validations. Molecular dynamics simulations were performed to check the stability of the noncovalent and covalent docked ligand-enzyme complexes and investigate the interaction patterns of the screened inhibitors. Finally, two compounds with novel aromatic backbones, reasonable interactions, and stable covalent binding modes were retained. These compounds can serve as potential hits for further biological evaluation.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [1] Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations
    Aibo Li
    Haopeng Sun
    Lei Du
    Xiaoxin Wu
    Jianqin Cao
    Qidong You
    Yuyan Li
    [J]. Journal of Molecular Modeling, 2014, 20
  • [2] Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation
    Alamri, Mubarak A.
    ul Qamar, Muhammad Tahir
    Afzal, Obaid
    Alabbas, Alhumaidi B.
    Riadi, Yassine
    Alqahtani, Safar M.
    [J]. JOURNAL OF MOLECULAR LIQUIDS, 2021, 330
  • [3] In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening
    Hadizadeh, Farzin
    Ghodsi, Razieh
    Mirzaei, Salimeh
    Sahebkar, Amirhossein
    [J]. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [4] Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
    Wang, Jhih-Lun
    Liu, Hsuan-Liang
    Zhou, Zheng-Li
    Chen, Wei-Hsi
    Ho, Yih
    [J]. MOLECULAR SIMULATION, 2015, 41 (04) : 287 - 297
  • [5] Discovery of novel HPPD inhibitors based on a combination strategy of pharmacophore, consensus docking and molecular dynamics
    Wang, Jia-Yu
    Zhao, Li-Xia
    Shi, Juan
    Gao, Shuang
    Ye, Fei
    Fu, Ying
    [J]. JOURNAL OF MOLECULAR LIQUIDS, 2022, 362
  • [6] Identification of novel covalent JAK3 inhibitors through consensus scoring virtual screening: integration of common feature pharmacophore and covalent docking
    Qiu, Genhong
    Yu, Li
    Jia, Lei
    Cai, Yanfei
    Chen, Yun
    Jin, Jian
    Xu, Lei
    Zhu, Jingyu
    [J]. MOLECULAR DIVERSITY, 2024,
  • [7] Discovery of Novel Nonpeptidic Proteasome Inhibitors Using Covalent Virtual Screening and Biological Evaluation
    Zhou, Jiao
    Sang, Xiaohong
    Wu, Meixian
    Qian, Tingli
    Ciechanover, Aaron
    An, Jing
    Xu, Yan
    Huang, Ziwei
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2024,
  • [8] Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors
    Lotfi, Bourougaa
    Mebarka, Ouassaf
    Khan, Shafi Ullah
    Htar, Thet Thet
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (10): : 5308 - 5320
  • [9] Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations
    Zhang, Yi
    Zhang, Ting-jian
    Tu, Shun
    Zhang, Zhen-hao
    Meng, Fan-hao
    [J]. MOLECULES, 2020, 25 (18):
  • [10] Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors
    Nassar, Husam
    Sippl, Wolfgang
    Dahab, Rana Abu
    Taha, Mutasem
    [J]. RSC ADVANCES, 2023, 13 (17) : 11278 - 11290